Aptevo Therapeutics (NASDAQ:APVO) Given New $8.00 Price Target at Roth Mkm

Aptevo Therapeutics (NASDAQ:APVO) had its price target decreased by investment analysts at Roth Mkm from $15.00 to $8.00 in a research report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com began coverage on shares of Aptevo Therapeutics in a report on Thursday. They issued a “sell” rating on the stock.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock traded up $0.01 during mid-day trading on Monday, reaching $0.18. 139,646 shares of the company’s stock were exchanged, compared to its average volume of 2,600,018. The business’s fifty day simple moving average is $0.37 and its 200 day simple moving average is $1.23. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $21.56.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.26. As a group, analysts anticipate that Aptevo Therapeutics will post -4.3 EPS for the current year.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.